Strategic partnerships BioAffinity is actively engaging with established institutions and government partners, evidenced by a U.S. Army study collaboration and participation in major medical symposia, signaling opportunity for co-development, pilot programs, and broader distribution of CyPath Lung through institutional channels.

Clinical adoption The CyPath Lung test is licensed as a Laboratory Developed Test and has demonstrated high sensitivity and specificity for early lung cancer detection, creating a compelling case for selling to hospitals, cancer centers, and radiology groups seeking noninvasive diagnostic options to improve accuracy and patient outcomes.

Clinical advisory Expansion of medical and scientific advisory board with prestigious institutions positions BioAffinity for credibility and introductions to key clinicians, enabling targeted outreach to early adopters in oncology and pulmonology markets.

Geographic strategy Recent patent activities and international interest, including an Australian patent application, suggest expansion potential beyond the U.S., offering cross-border sales opportunities and partnerships with international distributors or licensed labs.

Funding momentum Visible fundraising activity and planned financing indicate available capital for market expansion, clinical studies, and scaling sales teams, presenting a favorable window for aggressive outreach to hospital systems, diagnostic labs, and managed care networks.